Идёт набор NCT06667960

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Фаза I / Фаза II С лечением Solid Tumor

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: JK06.
Кому может быть актуально: Состояния в реестре: Solid Tumor. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Бельгия, Испания
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Обзор

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.

Подробное описание

This Phase 1/2, open label, dose escalation and cohort expansion study is designed to evaluate and characterize the safety, tolerability, PK, immunogenicity, and preliminary anti-tumor activity of JK06 administered intravenously (IV) in patients with unresectable, locally advanced, or metastatic cancer. The study consists of a Dose Escalation phase to determine the MTD/recommended phase 2 dose (RP2D) of JK06, followed by a Cohort Expansion phase to further define the safety and initial efficacy of JK06 in tumor specific cohorts.

Вмешательства

Препарат JK06
Biparatopic anti-5T4 antibody

Первичные конечные точки

Dose-limiting Toxicity (DLT) [Срок оценки: First 21 days of treatment.]
Dose-Finding [Срок оценки: From First Patient Dosed to end of Escalation, up to 14 months.]
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Срок оценки: First treatment through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.]
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Срок оценки: Screening date through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.]
Objective Response Rate (ORR) [Срок оценки: From date of randomization until the date of first documented progression, assessed up to 104 weeks]

Вторичные конечные точки (6)

Pharmacokinetics of JK06 [Срок оценки: Day 1 of dosing through 7 days post last dose.]
Pharmacokinetics of JK06 [Срок оценки: Day 1 of dosing through 7 days post last dose.]
Immunogenicity of JK06 by blood level measurement [Срок оценки: Day 1 of dosing through 7 days post last dose.]
Progression Free Survival (PFS) [Срок оценки: "From date of randomization until the date of first documented progression, assessed up to 104 weeks]
Duration of Response (DOR) [Срок оценки: From date of randomization until the date of first documented progression, assessed up to 104 weeks]
Disease Control Rate (DCR) [Срок оценки: Time of initial response (CR or PR) documentation (in patients who have a subsequent confirmation of objective response) to the time of confirmed progressive disease using RECIST 1.1, or death, whichever occurs first.]

Критерии участия

Критерии включения

Age ≥ 18 years old.
Signed informed consent and willing and able to comply with study procedures and scheduled visits.
For Dose Escalation, patients with histologically diagnosed unresectable, locally advanced, or metastatic solid tumors.
Dose expansion solid tumor groups.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
Life expectancy ≥ 12 weeks.
Measurable disease as per RECIST 1.1 criteria and documented by CT and/or MRI. Note: lesions treated previously with radiation must demonstrate clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.
Acceptable laboratory parameters:

Albumin ≥ 2.8 g/dL.
Platelet count ≥ 100, 000.
Hemoglobin ≥ 9.0 g/dL.
Absolute neutrophil count ≥ 1,500/μL.
ALT/AST ≤ 3.0 times ULN.

\- ALT/AST ≤ 5 × ULN for patients with liver metastases.

Total bilirubin ≤ 1.5 ULN or ≤ 3 x ULN for patients with Gilbert's disease.
Direct bilirubin ≤ 1.5 ULN for patients with total bilirubin > 1.5 ULN.
Creatinine ≤ 1.8 mg/dL. -Or calculated/measured creatinine clearance > 30 mL/minute.
Identification of an archival tumor sample (i.e., tissue block (formalin-fixed paraffin-embedded \[FFPE\]) or a series of approximately 10-15 slides).
Consent to pre-treatment fresh tumor biopsy for patients enrolled in the back-fill part of Dose Escalation and all eligible patients enrolled in Cohort Expansion.
Women of childbearing potential (WOCBP) not surgically sterilized and between menarche and 1 year post menopause must have a negative serum or urine pregnancy test and be willing to use 2 forms of effective contraception throughout the study starting with screening through 217 days after the last dose of JK06.
Male patients with partners of childbearing potential, even if surgically sterilized (i.e., status post-vasectomy) must agree to contraceptive use from the time of consent through 217 days after treatment discontinuation.
Central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet certain criteria at the time of enrollment.
Must be willing and able to comply with clinic visits and procedures outlined in the study protocol.
Concurrent use of hormones for breast cancer or for non-cancer related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates or RANK-L inhibitors or analogues are permitted for supportive care of patients with bone metastases.

Критерии исключения

Patients with symptomatic or unstable CNS primary tumor or metastases and/or carcinomatous meningitis. Patients with documented treated CNS metastases stable for at least 4 weeks may be enrolled at the discretion of the investigator.
Major surgery within 6 weeks from treatment initiation.
Clinically significant cardiovascular/vascular disease ≤ 6 months before first dose.
Clinically significant gastrointestinal disorders.
Clinically significant pulmonary compromise requiring supplemental oxygen use.
Grade 2 or greater peripheral neuropathy at time of study entry.
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
Known hypersensitivity to JK06 or any excipient.
Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma skin cancer, cervical carcinoma in situ, resected melanoma in situ, or any malignancy considered to be indolent and never required therapy.
Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the patient to receive or tolerate the planned treatment.
Recent or ongoing serious infection.
Prior systemic anti-cancer treatment:

For cytotoxic chemotherapy, small molecule inhibitors, radiation, or similar investigational treatments, ≤ 2 weeks or 5 half-lives, whichever is shorter.
For monoclonal antibodies or similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.
Ascites or pleural effusions requiring large volume para- or pleurocentesis within 4 weeks of treatment initiation.
Pregnant or nursing.
Therapeutic anticoagulation for a thromboembolic event that occurred within 3 months of dosing; prophylactic anticoagulation is permitted.
Active pneumonitis/interstitial lung disease (ILD) or history of drug-induced or radiation-induced pneumonitis/ILD that requires ongoing systemic corticosteroid treatment or has not fully resolved at study entry.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет